Heinrich Haas
Chief Technology Officer NeoVac
Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.
Seminars
Wednesday 23rd September 2026
Engineering LNPs for Next Generation Vaccines & Therapeutics
12:00 pm
- Rational design approaches are applied for tailoring lipid and LNP architecture
- Tailored formulations with tunable immunogenicity and precise targeting specificity are provided
- Formulations allow for repeat dosing in therapeutic settings
- Improved safety and reduced reactogenicity were demonstrated in a clinical study
